Encap, the international drug delivery solutions provider, announced today that it has signed a Head of Terms with Kenmore Capital Oakbank Ltd and secured a long-term lease for a new 14,000 sq. ft facility at Oakbank Park Way, Livingston, Scotland. The site is adjacent to Encap’s current R&D and production plant and will contain additional microbiology and developmental laboratories, state-of-the-art capsule filling suites and dedicated cytotoxic units.

Notes to Editors

Encap is an international drug delivery solutions provider with fully integrated capabilities in oral drug delivery, contract development and commercial manufacture. Encap is a world leader in liquid-filled two-piece capsules. Established in 1989, the Company is headquartered near Edinburgh, Scotland and offers capsule development and commercial manufacture for NCEs and marketed small molecules, biologicals and nutraceuticals on a fee-for-service basis. The Company’s current commercial production capacity exceeds 300 million capsules per annum.

Encap also partners companies throughout Europe, North America and Asia to improve the oral delivery of developmental candidates and extend the lifecycles of existing products. The Company’s proprietary technologies include liquid-fill, DuoCaps, Abusolve ™ and LayerCap ™ .

For more information, please contact

t : +44 (0) 1506 448080

f : +44 (0) 1506 448081
e: enquiry@encapdrugdelivery.com